Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / G.I. and Other Associated Cancers Research Group / Discovered GP73 as a classifier of HCC in high risk patients and demonstrated that it improves AFP performance in detecting early stage HCC.

Discovered GP73 as a classifier of HCC in high risk patients and demonstrated that it improves AFP performance in detecting early stage HCC.

GP73 was approved for HCC screening in China in combination with AFP.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.

Announcement 10/27/2016

Thank you to everyone who contributed to the successful and productive EDRN Orientation Meeting in October. The next EDRN Steering Committee Meeting will take place in March 6-9, 2017 in Tempe, AZ. More information about this meeting will be available soon.

Announcement